EC Number |
Inhibitors |
Structure |
---|
3.4.21.98 | (10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-oxo-2,7-dioxa-8-thia-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide 8,8-dioxide |
- |
|
3.4.21.98 | (10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2,7-dioxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide |
- |
|
3.4.21.98 | (10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(dimethylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide |
- |
|
3.4.21.98 | (10S,13S)-10-cyclohexyl-N-(1-[[(2-[[(1S)-2-(methylamino)-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-8,11-dioxo-2-oxa-9,12-diazabicyclo[13.3.1]nonadeca-1(19),15,17-triene-13-carboxamide |
- |
|
3.4.21.98 | (11R,14R)-N-(1-[[(2-[[(1R)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-cyclohexyl-9,12-dioxo-2-oxa-10,13-diazabicyclo[14.3.1]icosa-1(20),16,18-triene-14-carboxamide |
- |
|
3.4.21.98 | (11S,14S)-N-(1-[[(2-[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]-2-oxoethyl)amino](oxo)acetyl]butyl)-11-cyclohexyl-9,12-dioxo-1,10,13,17-tetraazabicyclo[14.2.1]nonadeca-16(19),17-diene-14-carboxamide |
- |
|
3.4.21.98 | (11Z,13aR,15aS)-N-(cyclopropylsulfonyl)-2-([7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy)-15-oxo-1,2,3,7,8,9,10,12a,13,14,15,15a-dodecahydrocyclopropa[f]pyrrolo[1,2-b][1,2,5]thiadiazacyclotetradecine-13a(6H)-carboxamide 5,5-dioxide |
most potent inhibitor of the series with sulfonamide linkage. The microsomally predicted clearance numbers is 0.17/0.7 L/h/kg (h/r) |
|
3.4.21.98 | (11Z,13aR,15aS)-N-(cyclopropylsulfonyl)-2-([7-methoxy-8-methyl-2-[4-(propan-2-yl)-1,3-thiazol-2-yl]quinolin-4-yl]oxy)-5,15-dioxo-1,2,3,5,6,7,8,9,10,12a,13,14,15,15a-tetradecahydro-13aH-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclotetradecine-13a-carboxamide |
inhibitor with proline amide linkage, slightly more potent than inhibitors with sulfonamide linkage. The microsomally predicted clearance number is 0.17/0.82 L/h/kg (h/r) |
|
3.4.21.98 | (1aR,5S,10R,22aR)-5-tert-butyl-9-cyclopropyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide |
- |
|
3.4.21.98 | (1aR,5S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide |
- |
|